New Three-Drug combo aims to control rare blood cancer with fewer harsh side effects
NCT ID NCT03620903
Summary
This study is testing whether a combination of three targeted drugs—bortezomib, rituximab, and ibrutinib—can effectively control Waldenström's macroglobulinemia, a rare blood cancer, without using traditional chemotherapy. The goal is to see if this 'chemotherapy-free' approach works as well as standard treatments while causing fewer severe side effects, which is especially important since many patients are older. The trial will enroll 53 adults who have not yet received any treatment for their condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
'Alexandra' General Hospital of Athens
Athens, 11528, Greece
-
DIAKO Ev. Diakonie-Krankenhaus gGmbH, Med. Klinik II
Bremen, 28239, Germany
-
Gemeinschaftspraxis Dres. Rudolf Schlag, Björn Schöttker, Joachim Haas
Würzburg, 97080, Germany
-
Hämato-Onkologische Gemeinschaftspraxis Pasing-Fürstenfeldbruck
München, 81241, Germany
-
Kliniken Maria Hilf GmbH (Krankenhaus St. Franziskus), Medizinische Klinik I (Klinik f. Hämatologie, Onkologie, Gastroentereologie)
Mönchengladbach, 41063, Germany
-
Kliniken Ostalb Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin
Mutlangen, 73557, Germany
-
Klinikum der Universität München, Medizinische Klinik und Poliklinik III
München, 83177, Germany
-
Studiengesellschaft Onkologie Bielefeld GbR
Bielefeld, 33604, Germany
-
Universitätsklinikum Halle, Klinik für Innere Medizin IV
Halle, 06120, Germany
-
Universitätsklinikum Münster, Med. Klinik A
Münster, 48149, Germany
-
Universitätsklinikum Ulm; Klinik für Innere Medizin Innere Medizin III
Ulm, 89081, Germany
-
Universtätsmedizin Mannheim, III. Medizinische Klinik Studienzentrale im MCC
Mannheim, 68167, Germany
Conditions
Explore the condition pages connected to this study.